Becker's ASC

ACG revises CRC screening guidelines, supports starting screening at 45 for average-risk patients, doesn’t recommend blood-based screening test

ACG posed several key questions and developed practical recommendations for practice providers. The recommendations were crafted through a focused literature search and supplemented by existing ...
Nasdaq

Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People

MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
Healio

Blood-based CRC screening test identifies asymptomatic, low-grade tumors

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...
Becker's ASC

Next-generation CRC test earns FDA approval

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...
Medscape

FDA OKs Next-Gen Cologuard Test for CRC Screening

The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...
Healio

Genescopy encourages colonoscopy with noninvasive CRC screening test

Please provide your email address to receive an email when new articles are posted on . Geneoscopy Inc. announced favorable results from its CRC-PREVENT trial, which assessed noninvasive, stool-based, ...
Business Wire

PREEMPT CRC™ Trial for Blood-Based Test to Detect Colon Cancer Has Expanded to Enroll Patients From Anywhere in the Continental U.S. During COVID-19 Pandemic

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
Business Wire

Freenome Announces Initiation of the PREEMPT CRC Clinical Trial, a Registrational Study for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
Medscape

Cell-Free DNA Blood Test Shows Strong Performance in Detecting Early-Stage CRC

A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.
MedPage Today

Blood Test for CRC Screening Lags Behind Other Options in Cost-Effectiveness Study

In a comparison against multiple alternative screening strategies, a cell-free DNA blood test (cf-bDNA) prevented the fewest cancers and cancer-specific deaths versus no screening. With an estimated ...
Morningstar

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...